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Cautionary Tales in the Interpretation of Clinical
Studies Involving Older Persons
Ian A. Scott, MBBS, FRACP, MHA, MEd; Gordon H. Guyatt, MD, MSc, FRCPC
T he care of patients 65 years or older presents a challenge for evidence-based medi-cine. Such patients are underrepresented in clinical trials, are more vulnerable totreatment-induced harm, and often are unable to fully participate in treatment deci-sions. We outline several cautionary themes in the interpretation of clinical studies
of therapeutic interventions involving older persons as they apply to processes of everyday clini-
cal decision making. In particular, we focus on issues of study design and quality of evidence,
choice of outcome measures, missing outcome data, assessment of potential harm, quantifying
treatment effects in individual patients (and adjusting these for effect modifiers and reduced life
expectancy), eliciting patient values and preferences, prioritizing therapeutic goals and selection
of treatments, and assisting patients in adhering to agreed therapeutic regimens.
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Evidence-based medicine (EBM) has
been defined as the judicious and sys-
tematic application of research evidence
to the care of individual patients inte-
grated with clinical judgment, expertise,
and patient values and preferences.1 The
care of patients 65 years or older pre-
sents a challenge for EBM because these
patients are underrepresented in clinical
trials.2 Older patients can exhibit unpre-
dictable treatment responses,3,4 often ex-
perience multiple comorbidities, have re-
stricted life spans, and may be unable to
participate in treatment decisions.Only 5%
of randomized controlled trials (RCTs) re-
ported in 4 major journals in 2004 were
designed specifically for older patients,5
and 72% of trials reported in 9major jour-
nals between 1994 and 2006 excluded
older patients.6 This exclusion is often
poorly justified, especially because most
older patients want to participate in clini-
cal trials and becausemethods for enhanc-
ing their recruitment are available.7
These limitations have caused some
physicians to question the relevance of
EBM to the care of older persons.8-11 If
one (inappropriately) regards EBM as
synonymous with practice guidelines,
one could point to disease-specific guide-
line recommendations based on evidence
thatmaynot apply to older cohorts.12Other
factors for which it is difficult to blame
EBM—pay-for-performance incentives,13
media influence, pressure from family, and
pharmaceutical industry advocacy—may
promote potentially inappropriate poly-
pharmacy as physicians are exhorted to de-
liver care on the basis of “evidence” that
may be inapplicable to older patients.14
In this article, we discuss several cau-
tionary themes in the interpretation of
clinical studies involving older persons,
focusing on therapeutic interventions.
We relate these themes to everyday clini-
cal decision making15 and highlight ways
in which physicians can more accurately
interpret and apply trial results to the
care of older persons (Table 1).
STEPS IN THERAPEUTIC
DECISION MAKING
Determining the Benefits
and Harms of Treatments as
Assessed in Clinical Studies
Interpreting evidence from the pub-
lished literature that addresses the ben-
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efits and harms of treatments ap-
plied to older patients requires an
appreciation of study characteris-
tics that may limit the validity and
applicability of their results.
Study Design and Quality
of Evidence
The risk of bias in clinical trials will
vary according to study design: ran-
domized trials are much less vul-
nerable to bias than are observa-
tional studies.
Randomized Controlled Trials
Large pragmatic RCTs16-20 that have
exclusively or predominantly en-
rolled older patients provide high-
quality evidence to inform treat-
ment decisions (Table 2). These
include drug withdrawal trials that
help identifymedications that can be
safely discontinued in older pa-
tients.21 Because treatment effectmay
differ across the broad range of ages
that fall under the label “elderly,” the
inclusion in such trials of prespeci-
fied age-stratified analyses (eg, 65-
74, 75-85, and85 years) adds fur-
ther to their information value.
Meta-analysis of Individual
Patient Data From RCTs
Even higher-quality evidence comes
frommeta-analyses of individual pa-
tient data from RCTs with similar
study objectives and design wherein
results have been stratified accord-
ing to age. Also of high quality are
summary results of aggregated data
for age-specific subgroups from sys-
tematic reviews ormegatrials that in-
volve large numbers of patients. In
most cases, such analyses show that
treatment effects, usually reported as
relative risk (RR) or RR reduction
(RRR), donot vary significantlywith
age. Nevertheless, physicians must
be alert to the occasional excep-
tions where age itself seems tomod-
ify treatment effects (Table 3).22-24
It is wisest to assume similar rela-
tive treatment effects in older and
younger patients unless there is com-
pelling evidence of age-related dif-
ferences. If differences are seen in
subgroup analyses, they are more
likely to be real if they meet the fol-
lowing criteria: one of a small num-
ber of prespecified analyses, de-
rived fromwithin-trial comparisons,
clinically and statistically signifi-
cant, consistent across studies, and
supported by other evidence relat-
ing to mechanism of action and
physiologic effects.25
Observational Studies
If data from RCTs involving older
patients are lacking, physiciansmust
turn to much lower-quality evi-
dence from large observational stud-
ies. Here, clinical registries are used
to assess treatment effects usingmul-
tivariate regression models. For ex-
ample, Setoguchi et al26 examined
21 484 patients (mean age, 80 years)
with myocardial infarction re-
cruited during a 10-year period and
found that risk-adjusted mortality
declined by 18% in relative terms
across 5 years after the index event
in response to significantly increas-
ing rates of use of antiplatelet agents
(from 3% to 51%), statins (from 8%
to 51%), -blockers (from 42% to
Table 1. Decision Steps, Barriers, and Potential Solutions in the Application of Evidence-Based Medicine to Older Populations
Decision Steps After Diagnosis Barriers Potential Solutions
What are the relative benefits and harms
of potential treatments as assessed in
clinical trials?
Underrepresentation of older patients in trials
Explanatory study designs limiting
generalizability of results
Surrogate or invalidated symptom-based
outcome measures
Loss to follow-up
Underreporting of adverse effects
Note trials that exclusively or predominantly enroll older patients.
Identify older patient subgroup analyses in trials/reviews.
Assume that relative effects are the same and consider older
patients’ increase in baseline risk.
Be aware that characteristics of patients entered into trials may be
substantially different from those in clinical practice.
Do not trust surrogate outcomes. Be wary of trials in which validity,
responsiveness, and interpretability of measures of change in
health status have not been established.
Consider the vulnerability of trials to show outcomes different from
those reported in patients lost to follow-up.
Scrutinize trials for their rigor in reporting adverse outcomes. Note
population-based, longitudinal studies with adverse event
monitoring as the main objective.
What are the absolute levels of benefit
and harm in my individual patient?
Underreporting of absolute risk (vs relative risk)
Unstudied factors that modify treatment effects:
-Competing disease risks
-Time-dependent changes in risk
-Variation in risk-treatment thresholds
Use validated risk prediction rules or scores, and calculate absolute
risk reduction.
Assess trials for use of expected event-free, quality-adjusted life
gain methods in quantifying treatment benefits.
What are the values and preferences of
my patient?
Limited health literacy and avoidance of decision
participation
Opinions of surrogate decision makers may not
reflect those of patients
Use validated decision aids to aid understanding of risk and benefit.
Retrieve population-based studies of elderly health values wherever
possible. Critically appraise the validity of surrogate opinions.
Adopt consensus approaches that are more likely to give stable,
consistent views of patient preferences.
What are the treatments that should take
priority over others?
Disease-specific clinical practice guidelines may
exacerbate the problem of polypharmacy and
drug-related adverse events
Retrieve guidelines that focus on older populations and ensure that
treatment burden and inconvenience receive adequate
consideration in decision making.
Will my patient be capable of adhering to
treatment?
Uncertainty regarding enablers and barriers to
adherence
Use validated adherence-enhancing strategies.
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72%), and angiotensin-converting
enzyme inhibitors and angiotensin
receptor blockers (from 39% to
50%). These same drugs have been
shown to be effective in secondary
prevention studies involving
younger patients.
In an even older cohort, Skol-
nick et al27 used data from the
CRUSADE (Can Rapid Risk Strati-
fication of Unstable Angina Pa-
tients Suppress Adverse Outcomes
with Early Implementation of the
ACC/AHA Guidelines) registry to
study 2 groups of patients with
non–ST elevation acute coronary
syndromes: those aged 75 to 89 years
(n=46 270) and those 90 years or
older (n=5557). They found that ad-
ministering aspirin,-blockers, and
early coronary angiography was as-
sociated with the same RRR in in-
hospital mortality in both groups;
that administering heparin was as-
sociated with no effect in either
group; and that administering gly-
coprotein IIB IIIA inhibitors was as-
Table 2. Selected Trials Specific to Older Populations
Source Aims Study Population Intervention and Comparator Outcomes
Beckett
et al,16
2008
To determine the efficacy
of hypertension
treatment
3845 patients aged80 y with
systolic blood pressure of
160-199 mm Hg. Patients with
recent stroke, secondary or
accelerated hypertension, heart
failure, or renal impairment were
excluded.
Sustained-release indapamide,
1.5 mg/d vs placebo. If the
target blood pressure of
150/80 mm Hg was not
achieved, perindopril (2 or
4 mg) or matching placebo
could be added.
During mean follow-up of 2.1 y, intervention
group vs placebo group had lower rates of
fatal stroke (6.5% vs 10.7%), all-cause
mortality (47.2% vs 59.6%), heart failure
(5.3% vs 14.8%), and any cardiovascular
event (33.7% vs 50.6%) (P .05 for all).
Shepherd
et al,17
2002
To determine the efficacy
of statin treatment in
patients with, or at high
risk for, cardiovascular
disease
5804 patients aged 70-82 y with a
history of, or risk factors for,
vascular disease. Patients with
cognitive dysfunction
(Mini-Mental State Examination
score24) were excluded.
Pravastatin, 40 mg/d vs placebo. During mean follow-up of 3.2 y, intervention
group vs placebo group had a 15% lower
rate of primary end point (composite of
coronary death, nonfatal MI, and fatal and
nonfatal stroke), a 19% lower rate of
coronary death and nonfatal MI, and a 24%
lower rate of coronary death (P .05 for
all). Stroke risk was unaffected.
Keime-
Guibert
et al,18
2007
To determine the efficacy
of radiotherapy for
glioblastoma
85 patients aged70 y with newly
diagnosed anaplastic
astrocytoma or glioblastoma.
Patients with Karnofsky
performance score70 were
excluded.
Supportive care plus radiotherapy
(focal radiation in daily
fractions of 1.8 Gy given
5 d/wk for a total dose of
50 Gy) vs supportive care
alone.
At median follow-up of 21 wk, intervention
group vs control group had a 53% decrease
in mortality (P=.002), with no severe
adverse events related to radiotherapy.
Results of quality-of-life and cognitive
evaluations across time did not differ
significantly between treatment groups.
Strandberg
et al,19
2006
To determine whether
better use of preventive
methods and treatments
of cardiovascular
disease reduces
cardiovascular events
and total mortality
400 patients aged75 y (mean
age, 80 y) with existing
cardiovascular disease (previous
MI, coronary artery disease, or
previous stroke, transient
ischemic attack, or peripheral
artery disease).
Optimization of pharmacologic
and nonpharmacologic
cardiovascular treatments by a
geriatrician in accordance with
current guidelines vs usual
care.
At mean follow-up of 3.4 y, there were no
significant differences between groups in
cardiovascular events or mortality, although
serum lipid levels and blood pressure were
better controlled in the intervention group.
Fletcher
et al,20
2004
To determine whether
universal
multidimensional
screening and geriatric
team-led management
reduces mortality,
admissions to the
hospital, or quality of life
43 219 patients aged75 y
attending 106 general practices.
Universal vs targeted assessment
and subsequent management
by a hospital outpatient
geriatric team vs a primary
care team. Cluster-randomized
factorial design.
At mean follow-up of 3 y, there were no
significant differences between groups in
mortality or in hospital or institutional
admissions. Significant improvements in
quality of life resulted from universal vs
targeted assessment in terms of home care
and from management by geriatric teams
vs primary care in terms of mobility, social
interaction, and morale.
Iyer et al,21
2008
To determine whether
drugs such as diuretics
and psychotropics can
be safely withdrawn in
selected patients
448 patients aged65 y living in
the community receiving thiazide
diuretics (4 RCTs); 697 patients
in residential care facilities
receiving benzodiazepines (2
RCTs) or psychotropic
medications (9 RCTs). Excluded
patients were those with stable
disease, receiving study drug for
at least 6 mo, and who had no
active indications for drug
continuation.
Continuation of medications or
withdrawal for4 wk.
In the thiazide withdrawal trials, 51%-100% of
patients could be withdrawn from the drug
for 6-52 wk with no adverse effects or rise
in blood pressure. In 2 trials, diuretics had
to be recommenced because of heart
failure, although no information reported on
concomitant use of standard antifailure
therapies, such as ACE inhibitors and
-blockers. In the benzodiazepine
withdrawal trials, no adverse reactions were
seen and, in 1 trial, marked reduction in
falls was seen (RR=0.34). In the
psychotropic withdrawal trials, there was
no significant change in behavior or
cognition except for 2 trials that reported
increased agitation/aggression and poor
sleep.
Abbreviations: ACE, angiotensin-converting enzyme; MI, myocardial infarction; RCT, randomized controlled trial; RR, relative risk.
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sociated with an excess number of
deaths in the oldest patients.
Choice of Outcome Measures
Many trials involving older pa-
tients assess treatment effect on qual-
ity of life (QOL), that is, alleviation
of symptoms, cognitive decline, and
functional impairment. Such sub-
jectivemeasures rely on patient self-
report or that of proxies such as fam-
ily members and caregivers. Such
measures are potentially imprecise
and are often not transparent or eas-
ily interpretable. The accuracy and
reproducibilityofQOLmeasuresmay
not be explicit or formally evalu-
ated. Thedefinitionofwhat informed
patients (or proxies) perceive as a
minimal important difference (MID)
in treatment effect may also not be
specified or substantiated.28
Recent analyses suggest such
measures need greater standardiza-
tion and more appropriate use.29 In
a review of 57 RCTs of drugs for de-
mentia,30 less than half discussed
MID, and those that did used opin-
ion-based estimates of MID using
different measures of cognitive and
global function whose psychomet-
ric properties remain uncertain.31No
trial used formally derived and vali-
dated MID. Many of these trials re-
ported “positive” treatment effects
that, although statistically signifi-
cant, did not demonstrate effects that
are important to patients.32,33 In con-
trast, the few trials that used harder
end points, such as rates of death,
institutionalization, resource use,
and clinical events, showed no treat-
ment effect.34 Physicians and fami-
lies considering antidementia drug
use should be aware that patient-
important benefit has not been con-
vincingly demonstrated. This is even
more important if there is evidence
of possible drug-induced harm, such
as increased risk of syncope.35
Missing Outcome Data
In clinical trials, older patients are
more likely than younger patients to
be lost to follow-up because of with-
drawal as a result of cognitive de-
cline, onset of other symptomatic
diseases, or logistic impediments to
continued trial participation. Older
patients may also find it more diffi-
cult to fully adhere to the study pro-
tocol. Despite attempts to maxi-
mize adherence and follow-up, rates
of loss to follow-up may remain as
high as 20%.36Missing outcomedata,
especially if unequally distributed
between the different arms of a trial,
threaten trial validity. In such cir-
cumstances, investigators may use
statistical methods for imputing
missing data. Simple imputation
strategies, such as last observation
carried forward, are most com-
monly used and then comparedwith
complete case analyses whereby pa-
tients with missing data are ex-
cluded. However, simple imputa-
tion and complete case analyses are
prone to bias unlessmissing data can
be shown to occur at random, un-
related to patient characteristics,
symptoms, disease severity, group
Table 3. Selected Analyses That Indicate Variation in Treatment Effect According to Age
Source Trial Description Results of Whole-Cohort Analyses Results of Age-Stratified Analyses Comments
Pignon
et al,23
2009
To assess whether CABG
vs PCI in 7812 patients
with multivessel
coronary disease
reduced all-cause
mortality during 6 y
Compared with PCI, CABG was
associated with a nonsignificant
decrease in deaths (ARR=1%;
RRR=9%; P=.12).
Individual patient data from 10 trials were analyzed
according to age55 y (n=2185), 55-64 y
(n=2933), and65 y (n=2688). The RRR was
modified by age with significant RR increase in death
from CABG of 25% in patients55 y, significant
RRR of 10% in patients 55-64 y, and significant RRR
of 18% in patients65 y. Test for age-treatment
interaction was significant (P=.002). Treatment
effect was not modified by number of diseased
vessels or any other baseline characteristic.
Results suggest that, as age
increases, outcomes
improve with CABG
compared with PCI.
Younger patients (55 y)
do worse with CABG,
patients 55-64 y do better
with CABG, and patients
65 y derive the best
results from CABG.
Yusuf
et al,24
2001
To assess whether
concomitant LRTCT
vs LRT alone in 9615
patients with head and
neck cancer improved
overall survival during
5.6 y
Compared with LRT alone,
LRTCT was associated with
significantly fewer deaths
(RRR=19%; ARR=4%).
Individual patient data from 8 trials were analyzed
according to age50 y (n=2584), 50-60 y
(n=3306), 61-70 y (n=2698), and71 y (n=692).
The RRR was significant for all patients up to and
including 70 y (50 y: 25%; 50-60 y: 23%; 61-70 y:
11%), but in patients71 y, RRR was attenuated
and nonsignificant (3%). Test for age-treatment
interaction was significant (P=.02) and showed a
consistent trend (P=.003). Treatment effect was not
modified by sex, performance status, tumor stage,
or site.
Results show that there was a
progressive decrease in
mortality benefit with
increasing age, from 25%
in young patients to 3% in
the oldest patients.
Guyatt
et al,25
2008
To assess whether an
early invasive strategy
vs a conservative
strategy in 2220 patients
with non–ST-segment
elevation acute coronary
syndromes reduced the
risk of death, nonfatal
MI, or rehospitalization
for acute coronary
syndrome at 6 mo
Compared with the conservative
strategy, the early invasive
strategy had fewer events
(ARR=3.5%; RRR=22%).
Subgroup analysis of this large trial showed that,
compared with younger patients, patients65 y
showed greater benefit from an early invasive
strategy (ARR=5.0% vs 1.8%; RRR=41% vs 22%).
This benefit was even greater among those aged
75 y (ARR=10.1%; RRR=42%), for which the
age-treatment interaction was significant (P=.01).
However, this benefit coexisted with a significant
3-fold higher risk of major bleeding in patients aged
75 y (16.6% vs 6.5%).
Results suggest that the
efficacy of an early invasive
strategy increases with age,
but this is offset by an
increased risk of major
bleeding.
Abbreviations: ACE, angiotensin-converting enzyme; ARR, absolute risk reduction; CABG, coronary artery bypass graft; CI, confidence interval; CT, chemotherapy;
LRT, locoregional treatment; MI, myocardial infarction; PCI, percutaneous coronary intervention; RRR, relative risk reduction.
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assignment, or drug adverse ef-
fects. This is rarely, if ever, the case.
Multiple imputation is preferred
whereby several plausible values for
missing variables are imputed to cre-
ate multiple data sets that are then
appropriately combined using sta-
tistical software.37 Reanalyses of data
from 2 RCTs38,39 involving older pa-
tients revealed that treatment ef-
fects deemed significant on last ob-
servation carried forward analysis
were greatly attenuated or were ren-
dered nonsignificant when subject
to multiple imputation analysis.
ASSESSMENT
OF POTENTIAL HARM
Measuring Harm in Trials
Because the risk of harm from a new
treatment is potentially greater in
older patients than in younger ones,
trials should be vigilant in identify-
ing adverse effects hypothesized on
the basis of pharmacologic (in the
case of drugs) and physiologic (for
devices and physical therapies) fac-
tors. To date, most RCTs devote less
care and attention to measurement
of adverse effects than to measure-
ment of benefits.40 Longitudinal
population-based studies thatmoni-
tor adverse effects in real-world prac-
tice should supplement reporting of
harm outcomes in RCTs. In an in-
ception cohort study41 of 472 older
patients with atrial fibrillation com-
mencing warfarin therapy, the cu-
mulative incidence of major hem-
orrhage for patients 80 years or older
was 13.1 per 100 person-years vs 4.7
for those younger than 80 years
(P=.009). Increasing age, the first 90
days of warfarin therapy, and an in-
ternational normalized ratio of 4.0
or greater were associated with in-
creased bleeding risk.41
Considering the Potential
for Harm in Patient Groups
Excluded From Trials
Results of trials involving younger
patients should not be applied in-
discriminately to older patients who
do not meet trial eligibility criteria
without rigorous assessment of po-
tential harms. For example, the Ran-
domized Aldactone Evaluation
Study42 demonstrated reducedmor-
tality with spironolactone adminis-
tration in patients with congestive
heart failure whose average age was
60 years. Cohort studies subse-
quently revealed an “indication
drift,” with spironolactone being
used in older patients.43 In On-
tario, Canada, a more than 3-fold
post–Randomized Aldactone Evalu-
ation Study increase in spironolac-
tone prescribingwas observed in pa-
tients with congestive heart failure
whowere, on average, 13 years older
than trial patients. This was associ-
atedwith an almost 4-fold rise in the
numbers of hospitalizations and
deaths secondary to hyperkale-
mia,44 underlying the need for es-
pecially close monitoring in pa-
tient groups more vulnerable to
hyperkalemia.
Similarly, after trials involving
younger patients who showed less
propensity to gastrointestinal bleed-
ing, the use of cyclooxygenase-2 in-
hibitor agents increased in the gen-
eral population, in which most
people with arthritis are older than
65 years, resulting in a 10% in-
crease in total hospitalizations due
to nonsteroidal drug–induced bleed-
ing.45 Patients in trials and older pa-
tients living in the community are
likely to differ in comorbidity, co-
interventions, and intensity ofmoni-
toring, which, in turn, may alter the
balance between risk and benefit
when therapies are applied more
broadly.9
DETERMINING THE
ABSOLUTE LEVELS OF
BENEFIT AND HARM IN
INDIVIDUAL PATIENTS
Quantifying Benefit and Harm
on the Basis of Clinical Trials
Trial investigators should report treat-
ment effects in relative and absolute
terms. Thus, although RRR tends to
remain constant, absolute risk reduc-
tion in future events conferred by
treatment will increase in patients
with higher baseline risk. This treat-
ment-related absolute risk reduc-
tion then needs to be comparedwith
the absolute risks of treatment-
induced harm in deciding the extent
of net patient-important benefit.
Absolute risk reduction for an in-
dividual patient can be estimated by
multiplying theRRRderived fromthe
trial (which can be assumed, inmost
cases, to be the same irrespective of
disease severity) by the patient’s ab-
solute disease risk. The latter is cal-
culated using risk prediction rules or
scoring systems that include age as a
risk variable. For example, tools ex-
ist for predicting risk of stroke in pa-
tients with nonvalvular atrial fibril-
lation,46 carotid artery stenosis,47 and
recent transient ischemic attack.48
Similarly, tools exist for quantifying
absolute level of harm with specific
treatments, such as bleeding risk sec-
ondary to the use of warfarin49 or fi-
brinolytic agents50 and operative risk
associated with cardiac surgery51 or
coronary angioplasty.52
Consider thedecision to startwar-
farin therapy in a 78-year-old man
with nonvalvular atrial fibrillation
who has a history of hypertension,
ischemic stroke, diabetes mellitus,
renal insufficiency, and gastroin-
testinal bleeding. His CHADS2 (con-
gestiveheart failure,hypertension, age
older than 75 years, diabetes melli-
tus, and previous stroke or transient
ischemic attack) score46 is 4, suggest-
ing a thromboembolic stroke rate
of 9.1 per 100 patient-years, which
warfarin treatment will reduce by
approximately two-thirds. His
HEMORR2HAGES (hepatic or renal
disease, ethanol abuse, malignancy,
older age [age 75 years], reduced
platelet count or function, rebleed-
ing risk, hypertension [uncon-
trolled], anemia, genetic factors [CYP
2C9 single-nucleotide polymor-
phisms], excessive fall risk [includ-
ing neuropsychiatric disease], and
stroke) score49 is 4, suggesting awar-
farin-inducedbleeding rateof10.4per
100 patient-years. Such risk quanti-
fication enables patients and physi-
cians to more carefully consider the
benefit-risk trade-offs involved in
treatment decisions.
Adjustment for
Age-Related Infirmity
In assessing net benefit in indi-
vidual patients, risk related to spe-
cific diseases (disease risk) needs to
be integrated with age-related infir-
mity. As age increases, so does the
prevalence of physiologic impair-
ment (frailty), comorbidity, psycho-
logical impairment (depression and
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isolation), disability (limited activi-
ties of daily living), andcognitive im-
pairment. As a consequence of ex-
clusion criteria, age-related infirmity
in trial patientsmay be considerably
less than that in community pa-
tients.53 Increasingagecombinedwith
chronic disease and disability com-
pete with the disease in question in
lowering life expectancy. As a re-
sult, thepotential benefits of disease-
specific treatments in individuals be-
come increasingly smaller inabsolute
termsor arenever realizedduring the
patient’s remaining life span.54
For example, treatingmicroalbu-
minuria in diabetic patients takes up
to 10 years to achieve reductions in
overt nephropathy comparedwith 2
to3years to treathypertension inpre-
venting cardiovascular events.15
Simple-to-use prognostic indices that
combine age, comorbidity, and func-
tional status canprecisely estimate life
expectancy against which disease-
specific mortality and time to treat-
ment benefit can be compared.55,56
This approach has been used to de-
termine the minimum elapsed time
(or payoff time) at which cumula-
tive benefit exceeds cumulative harm
for specific care recommendations in
the presence of multiple comorbidi-
ties.57 Disease-specific risk indices
may also be helpful in identifying
patientswith a prognosis of less than
6 months in whom more conserva-
tive treatment regimensmay be pref-
erable.58
Adjustment for Other
Treatment Effect Modifiers
Challenges remain in dealing with
more complicated sets of circum-
stances in which (1) treatments may
affectQOLandsurvival to varyingde-
grees or indifferent directions; (2) in-
dividuals regularlymove into andout
of states of illness and functional im-
pairment59; and (3)multiplemedica-
tions prescribed for different dis-
eases compromise estimation of the
additive benefit from initiating new
drugs for newly diagnosed condi-
tions.60We await the development of
tools that can handle these situa-
tions in ways readily translatable to
everydaycare. In themore simplecase
in which immediate symptom con-
trol is the objective and treatment ef-
fects of single drugs are ascertain-
able and short-lived, n-of-1 trials in
which individuals serve as their own
controls and participate in ran-
domly sequenced periods of placebo
or active drug61 deserve wider use in
older populations.
Eliciting Patient Values
and Preferences
Empowering Patients. Physicians
must align treatment goals with the
values and preferences of older pa-
tients, who frequently place more
emphasis on QOL, functional sta-
tus, and independence than on sur-
vival or discrete clinical events.62
Treatment choices must reflect the
imposed burdens of treatment,
whichmay be considerable for older
patients and are often underappre-
ciated.63 Many are also limited in
their ability to participate in self-
care as a result of dementia, depres-
sion, or hearing or visual impair-
ment.64 Most, but not all, older
patients65 want to actively share in
therapeutic decisions involving risk-
benefit trade-offs. Assistive aids are
available that render information
about treatment options and poten-
tial risksmore comprehensible. They
engender greater confidence in de-
cisions that often eschewmore risky
interventions.66
For example, in a trial that evalu-
ated a decision aid for older pa-
tients with nonvalvular atrial fibril-
lation, patients demonstrated less
decisional conflict and were more
likely to choose against taking war-
farin comparedwith those subject to
guideline-based medical advice.67
Similarly, in another study68 of older
patients with atrial fibrillation, less
than half who opted for warfarin
therapy were actually receiving it,
whereasmore than half who did not
want it were prescribed the drug.
Only two-thirds of thewhole sample
preferred warfarin therapy, whereas
close to 80% would have met the
guideline criteria for eligibility.
Limitations of Surrogate Opinions.
Someolder patients areunable to en-
gage in decision making owing to
severe illness, low health literacy, or
cognitiveimpairment.Insuchcircum-
stances, and if no advance directives
are available, theattendingphysician
or surrogate decision makers must
makedecisionsonthepatient’sbehalf.
Inuptoathirdofcases, suchopinions
are at odds with what patients them-
selveswouldhavepreferred.69 Inpar-
ticular,olderpatients,eventhosewith
fair health, seemmuch lesswilling to
foregoasmuchadecrease in life span
inexchangeforexcellenthealthassur-
rogatesassume.70Consensus-basedap-
proachesthatreconcilewhat is incon-
testableaboutpatientpreferenceswith
theadviceofphysiciansandcaregivers
lessen the risk of ill-informed surro-
gate opinions taking undue prece-
dence in end-of-life decisions.71
Prioritizing Therapeutic Goals and
Selection of Treatments. Minimiz-
ing the Risks of Polypharmacy. Be-
cause the risk of harm in older pa-
tients increases in proportion to the
numberof treatmentsprescribed,72 it
is necessary to prioritize therapeutic
goalsandselectionof treatments.This
may run counter to recommenda-
tions of current disease-specific, evi-
dence-based guidelines endorsed by
specialty societies. For example, in a
cohort of older patients hospitalized
with heart failure and prescribed
guideline-based care from a special-
ist heart failure team, the average
number of cardiac drugs per patient
rose from 5.0 on admission to 6.6 at
discharge, associated with a 60% in-
crease in the number of potential
drug-drug interactions per patient
(from 5.0 to 8.0).73 In a hypothetical
79-year-old woman with 5 chronic
diseases described by Boyd et al,13
guideline-concordant care, if rigor-
ously applied, would mandate 12
medicines requiring19dosesperday
taken up to 5 times during a typical
day,with the potential formore than
20drug-disease,drug-drug,anddrug-
diet interactions.
Defining Care Goals and Prioritiz-
ing Treatments. How physicians pri-
oritize recommended treatments has
received little study.Theevidence that
does exist suggests that high-impact
treatments tend to be underrated,74
that more attention is given to long-
term rather than short-term treat-
ment goals,75 and that treatment pref-
erences are sensitive to physician age,
training, andpractice setting.76 A con-
struct has beenproposedwhereby life
expectancy, time to realization of
treatment benefit, primary goals of
care (prevention, cure, or pallia-
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tion), and validity of specific treat-
ment targets (such as hemoglobinA1c
levels in diabetes mellitus and blood
pressure in hypertension) are inte-
grated in determining appropriate
treatment for older individuals with
the aim of minimizing unwarranted
polypharmacy.77
Treatment choices need to be pri-
oritized according to the strength of
treatment recommendations. Strong
recommendations, if appropriately
developed, reflect a large gradient be-
tween desirable and undesirable pa-
tient-important effects and, thus, rep-
resent the preferred option for almost
all patients. In contrast, weak recom-
mendations indicate greater uncer-
tainty, or a closer balancebetweende-
sirable and undesirable effects.
Increasing use of theGRADE (Grad-
ing of Recommendations Assess-
ment, Development, and Evalua-
tion) systemby guideline developers
will help physicians and patients dis-
criminate between strong and weak
recommendations.78
Suchanapproachisparticularlyrel-
evant at a timewhenmany guideline
recommendations are still based on
lower-qualityevidence.79 Itmaylessen
the tension physicians feel between
avoidingpolypharmacywhilestill rec-
ommendinghighlyeffectivetreatments
ineligiblepatients.80 Inrecognitionof
this tension, some specialty societies
arenowproducingguidelinesspecific
toolderpopulations that incorporate
considerations of general health, co-
morbidities, cognitive status, and life
expectancy.81,82Asapracticalapplica-
tion, in a controlled trial83 that used
a drug-discontinuation algorithm
centered on an evidence-based con-
sensus around indications and net
benefit, 332 different drugs were
discontinued in 119 older disabled
patients (an average of 2.8 drugs per
patient). This resulted in significant
decreases in 12-month mortality
(21%vs 45%), referrals to acute care
facilities (12%vs30%),anddrugcosts
(decreaseof46¢ inaveragedailydrug
cost per patient).
Assisting Patients in Adhering to
AgreedTherapeuticRegimens. Inolder
patients,physicalfrailty, forgetfulness,
heightenedsensitivitytoevenmildad-
verse effects, and demands of every-
day life may result in nonadherence
ratesashighas84%.84Themoretreat-
mentsprescribed, thegreater the level
of nonadherence.85 Nonadherence is
typicallyunderreportedbypatientsand
is difficult to predict or detect.86 In a
reviewof8controlled trials involving
older patients,87 adherence was im-
proved in relative terms by amean of
11%bymeansof regularly scheduled
patient follow-up visits, multicom-
partment dose administration aids,
pharmacist-mediatedmedication re-
views,andgroupeducation.Multidis-
ciplinarychronicdiseasemanagement
programstargetedtohigh-riskpatients,
such as thosewith heart failure, have
alsobeenshowntoimproveadherence
andreducemortalityandreadmissions,
but they aremore resource intense.88
CONCLUDING COMMENTS
Irrespective of the patient’s age, po-
tentially relevant researchneeds tobe
critically appraised regarding valid-
ity, impact, andapplicability; and this
research needs to be presented to the
clinical end-user in a preprocessed
formthat is readily interpretable.Phy-
sicians who care for older patients
need to be adept at seeking out such
evidence.89 Becauseof thegreater risk
of harm and the lesser potential for
benefit in older patients and the
greater variability in treatment ef-
fects, thequalityof evidence support-
ing substantial benefit and limited
harm needs to be more stringent in
older vs younger populations. Ad-
ministering treatments in older pa-
tients, either empiricallybasedon the
presumed pathogenesis of the target
disease or on the basis of limited evi-
dence,may not be in their best inter-
ests.Physiciansneed tocarefully con-
sider their sources of evidence and
recommendations90 and to find the
right balance between avoiding the
“risk-treatment paradox”—high-
risk older patients being denied safe
medicationscapableofmaterially im-
proving survival or QOL91—while
avoiding inappropriate use of medi-
cations inwhichrisksare likely toout-
weighbenefit.92Clinicaldecisionmak-
ing should be informed, as much as
possible, by the best available evi-
dence.Whereevidence is lacking,aca-
demic physicians can assist in filling
the gaps by advocating the strategies
outlined in Table 4.93
Accepted for Publication: Novem-
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Table 4. Strategies for Improving the Evidence Base for Older Patient Care
Strategy
More meta-analyses of age-stratified individual patient data obtained from randomized trials that
include sizable numbers of older patients
More clinical trials (preferably randomized megatrials) specific to older patient populations in which:
• Trial populations are representative of community populations
• Age-based exclusions and other exclusions that disproportionately reduce enrollment of older
patients are eliminated where possible
• Nonpharmacologic treatments are given equal weighting to pharmacologic treatments
• Multidrug regimens are compared directly with simpler regimens
• Assessment of physical, psychological, cognitive, and other outcomes is routinely performed
using validated, standardized measurement tools
• Benefits and harms are rigorously evaluated and reported in absolute and relative terms
• Sample size calculations ensure adequate power for age-stratified analyses
• Minimal important difference has been prespecified for trials evaluating treatment effects on
patient-reported outcomes
• Prespecified subgroup analyses are performed to assess primary outcomes according to age
(65-74, 75-84, and85 y), treatment intensity or duration of follow-up, and selected
comorbidities or levels of premorbid function
More observational studies and clinical registries specific to older patients in which:
• Outcome measures are standardized and regularly include measures of physical, psychological,
and cognitive function
• Subgroup analyses are performed if possible as described previously herein
• Multivariate regression models are applied to whole cohorts and subgroups in identifying patient
types who are more likely to benefit (or be harmed) by treatments in question
More clinical practice guidelines that, regarding older patients:
• Use the GRADE system or a similar approach that makes explicit recommendations for which
there is compelling evidence of benefits substantially outweighing harm under most
circumstances
• Consider the limitations of applying multiple treatments to patients with multiple chronic diseases
Abbreviation: GRADE, Grading of Recommendations Assessment, Development, and Evaluation.
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ined the question of whether the albumin to creatinine
ratio (ACR) can help in risk stratification in elderly pa-
tients with diabetes mellitus and with varying levels of
eGFR.11 They reported that over half of the patients 75
years or older had CKD, similar to prior reports. Al-
though in younger age groups, the association between
ACR and death was stronger among patients with rela-
tively preserved eGFR and attenuated at lower eGFR, the
ACRwas independently associatedwith an increased risk
of death at all levels of eGFR among patients 75 years or
older. Thus, ACR may be a valuable tool for mortality
risk stratification in elderly patients, particularly among
the large group who meet the criteria for CKD owing to
a moderate reduction in eGFR. Given that proteinuria is
also a risk factor for progression to ESRD in most popu-
lations, it would be informative to determinewhether this
parameter helps to distinguish between the competing
risks of death and ESRD in the population of elderly pa-
tients with CKD.
Although this study addresses some of the issues re-
lated to interpretationofCKDamongelderlypatients,many
uncertainties still remain. What we can conclude, on the
basis of the studies in this issue of Archives and others, is
that CKD in elderly individuals has clinical implications
beyond ESRD, at least when the eGFR is below 45 mL/
min/1.73 m2 or is accompanied by proteinuria. In elderly
patients, wemay need to focus on prevention of mortality
and improvement inquality of life asmuchas, ormore than,
on prevention of progression to ESRD. Fortunately, these
goals often are not mutually exclusive.
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Correction
Incorrect Sources Cited in Table 3. In the Special Ar-
ticle titled “CautionaryTales in the Interpretation ofClini-
cal Studies Involving Older Persons” by Scott and Guy-
att, published in theApril 12th issue of theArchives (2010;
170[7]:587-595), the 3 sources cited in Table 3 on page
590 were incorrect. The sources should have read as fol-
lows, reading from the top to the bottom in the Source
column: Hlatky et al,22 2009; Pignon et al,23 2009; and
Yusuf et al,24 2001, respectively. The rest of the infor-
mation is accurate.
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